The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Autologous Cell Therapy Products Market Research Report 2024
Synopsis
Autologous cell therapy is a medical treatment approach that involves using a patient's own cells to treat a specific medical condition or promote healing. This type of therapy is personalized and based on the principle that cells from the patient's own body are less likely to trigger immune responses or rejection, making it a potentially effective and safe treatment option for various conditions.
Global Autologous Cell Therapy Products market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Autologous Cell Therapy Products market research.
Key manufacturers engaged in the Autologous Cell Therapy Products industry include Novartis, Gilead Sciences, Bristol-Myers Squibb, Johnson & Johnson, Autolus Therapeutics, FOSUNKite, JW Therapeutics, CARsgen Therapeutics and Sorrento Therapeutics, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Autologous Cell Therapy Products were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Autologous Cell Therapy Products market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Autologous Cell Therapy Products market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Gilead Sciences
Bristol-Myers Squibb
Johnson & Johnson
Autolus Therapeutics
FOSUNKite
JW Therapeutics
CARsgen Therapeutics
Sorrento Therapeutics
Mustang Bio
Cellectis
Allogene Therapeutics
Celyad Oncology
Bluebird Bio
Lonza
Segment by Type
Autologous Stem Cell Transplants
Autologous T Cell Therapies
Platelet-Rich Plasma (PRP) Therapy
Others
Segment by Application
Cancer
Hemophilia
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Autologous Cell Therapy Products report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Autologous cell therapy is a medical treatment approach that involves using a patient's own cells to treat a specific medical condition or promote healing. This type of therapy is personalized and based on the principle that cells from the patient's own body are less likely to trigger immune responses or rejection, making it a potentially effective and safe treatment option for various conditions.
Global Autologous Cell Therapy Products market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Autologous Cell Therapy Products market research.
Key manufacturers engaged in the Autologous Cell Therapy Products industry include Novartis, Gilead Sciences, Bristol-Myers Squibb, Johnson & Johnson, Autolus Therapeutics, FOSUNKite, JW Therapeutics, CARsgen Therapeutics and Sorrento Therapeutics, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Autologous Cell Therapy Products were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Autologous Cell Therapy Products market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Autologous Cell Therapy Products market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Gilead Sciences
Bristol-Myers Squibb
Johnson & Johnson
Autolus Therapeutics
FOSUNKite
JW Therapeutics
CARsgen Therapeutics
Sorrento Therapeutics
Mustang Bio
Cellectis
Allogene Therapeutics
Celyad Oncology
Bluebird Bio
Lonza
Segment by Type
Autologous Stem Cell Transplants
Autologous T Cell Therapies
Platelet-Rich Plasma (PRP) Therapy
Others
Segment by Application
Cancer
Hemophilia
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Autologous Cell Therapy Products report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Autologous Cell Therapy Products Market Overview
1.1 Product Overview and Scope of Autologous Cell Therapy Products
1.2 Autologous Cell Therapy Products Segment by Type
1.2.1 Global Autologous Cell Therapy Products Market Value Comparison by Type (2023-2029)
1.2.2 Autologous Stem Cell Transplants
1.2.3 Autologous T Cell Therapies
1.2.4 Platelet-Rich Plasma (PRP) Therapy
1.2.5 Others
1.3 Autologous Cell Therapy Products Segment by Application
1.3.1 Global Autologous Cell Therapy Products Market Value by Application: (2023-2029)
1.3.2 Cancer
1.3.3 Hemophilia
1.3.4 Others
1.4 Global Autologous Cell Therapy Products Market Size Estimates and Forecasts
1.4.1 Global Autologous Cell Therapy Products Revenue 2018-2029
1.4.2 Global Autologous Cell Therapy Products Sales 2018-2029
1.4.3 Global Autologous Cell Therapy Products Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Autologous Cell Therapy Products Market Competition by Manufacturers
2.1 Global Autologous Cell Therapy Products Sales Market Share by Manufacturers (2018-2023)
2.2 Global Autologous Cell Therapy Products Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Autologous Cell Therapy Products Average Price by Manufacturers (2018-2023)
2.4 Global Autologous Cell Therapy Products Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Autologous Cell Therapy Products, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Autologous Cell Therapy Products, Product Type & Application
2.7 Autologous Cell Therapy Products Market Competitive Situation and Trends
2.7.1 Autologous Cell Therapy Products Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Autologous Cell Therapy Products Players Market Share by Revenue
2.7.3 Global Autologous Cell Therapy Products Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Autologous Cell Therapy Products Retrospective Market Scenario by Region
3.1 Global Autologous Cell Therapy Products Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Autologous Cell Therapy Products Global Autologous Cell Therapy Products Sales by Region: 2018-2029
3.2.1 Global Autologous Cell Therapy Products Sales by Region: 2018-2023
3.2.2 Global Autologous Cell Therapy Products Sales by Region: 2024-2029
3.3 Global Autologous Cell Therapy Products Global Autologous Cell Therapy Products Revenue by Region: 2018-2029
3.3.1 Global Autologous Cell Therapy Products Revenue by Region: 2018-2023
3.3.2 Global Autologous Cell Therapy Products Revenue by Region: 2024-2029
3.4 North America Autologous Cell Therapy Products Market Facts & Figures by Country
3.4.1 North America Autologous Cell Therapy Products Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Autologous Cell Therapy Products Sales by Country (2018-2029)
3.4.3 North America Autologous Cell Therapy Products Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Autologous Cell Therapy Products Market Facts & Figures by Country
3.5.1 Europe Autologous Cell Therapy Products Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Autologous Cell Therapy Products Sales by Country (2018-2029)
3.5.3 Europe Autologous Cell Therapy Products Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Autologous Cell Therapy Products Market Facts & Figures by Country
3.6.1 Asia Pacific Autologous Cell Therapy Products Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Autologous Cell Therapy Products Sales by Country (2018-2029)
3.6.3 Asia Pacific Autologous Cell Therapy Products Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Autologous Cell Therapy Products Market Facts & Figures by Country
3.7.1 Latin America Autologous Cell Therapy Products Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Autologous Cell Therapy Products Sales by Country (2018-2029)
3.7.3 Latin America Autologous Cell Therapy Products Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Autologous Cell Therapy Products Market Facts & Figures by Country
3.8.1 Middle East and Africa Autologous Cell Therapy Products Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Autologous Cell Therapy Products Sales by Country (2018-2029)
3.8.3 Middle East and Africa Autologous Cell Therapy Products Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Autologous Cell Therapy Products Sales by Type (2018-2029)
4.1.1 Global Autologous Cell Therapy Products Sales by Type (2018-2023)
4.1.2 Global Autologous Cell Therapy Products Sales by Type (2024-2029)
4.1.3 Global Autologous Cell Therapy Products Sales Market Share by Type (2018-2029)
4.2 Global Autologous Cell Therapy Products Revenue by Type (2018-2029)
4.2.1 Global Autologous Cell Therapy Products Revenue by Type (2018-2023)
4.2.2 Global Autologous Cell Therapy Products Revenue by Type (2024-2029)
4.2.3 Global Autologous Cell Therapy Products Revenue Market Share by Type (2018-2029)
4.3 Global Autologous Cell Therapy Products Price by Type (2018-2029)
5 Segment by Application
5.1 Global Autologous Cell Therapy Products Sales by Application (2018-2029)
5.1.1 Global Autologous Cell Therapy Products Sales by Application (2018-2023)
5.1.2 Global Autologous Cell Therapy Products Sales by Application (2024-2029)
5.1.3 Global Autologous Cell Therapy Products Sales Market Share by Application (2018-2029)
5.2 Global Autologous Cell Therapy Products Revenue by Application (2018-2029)
5.2.1 Global Autologous Cell Therapy Products Revenue by Application (2018-2023)
5.2.2 Global Autologous Cell Therapy Products Revenue by Application (2024-2029)
5.2.3 Global Autologous Cell Therapy Products Revenue Market Share by Application (2018-2029)
5.3 Global Autologous Cell Therapy Products Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Novartis Autologous Cell Therapy Products Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Gilead Sciences
6.2.1 Gilead Sciences Corporation Information
6.2.2 Gilead Sciences Description and Business Overview
6.2.3 Gilead Sciences Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Gilead Sciences Autologous Cell Therapy Products Product Portfolio
6.2.5 Gilead Sciences Recent Developments/Updates
6.3 Bristol-Myers Squibb
6.3.1 Bristol-Myers Squibb Corporation Information
6.3.2 Bristol-Myers Squibb Description and Business Overview
6.3.3 Bristol-Myers Squibb Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Bristol-Myers Squibb Autologous Cell Therapy Products Product Portfolio
6.3.5 Bristol-Myers Squibb Recent Developments/Updates
6.4 Johnson & Johnson
6.4.1 Johnson & Johnson Corporation Information
6.4.2 Johnson & Johnson Description and Business Overview
6.4.3 Johnson & Johnson Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Johnson & Johnson Autologous Cell Therapy Products Product Portfolio
6.4.5 Johnson & Johnson Recent Developments/Updates
6.5 Autolus Therapeutics
6.5.1 Autolus Therapeutics Corporation Information
6.5.2 Autolus Therapeutics Description and Business Overview
6.5.3 Autolus Therapeutics Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Autolus Therapeutics Autologous Cell Therapy Products Product Portfolio
6.5.5 Autolus Therapeutics Recent Developments/Updates
6.6 FOSUNKite
6.6.1 FOSUNKite Corporation Information
6.6.2 FOSUNKite Description and Business Overview
6.6.3 FOSUNKite Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.6.4 FOSUNKite Autologous Cell Therapy Products Product Portfolio
6.6.5 FOSUNKite Recent Developments/Updates
6.7 JW Therapeutics
6.6.1 JW Therapeutics Corporation Information
6.6.2 JW Therapeutics Description and Business Overview
6.6.3 JW Therapeutics Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.4.4 JW Therapeutics Autologous Cell Therapy Products Product Portfolio
6.7.5 JW Therapeutics Recent Developments/Updates
6.8 CARsgen Therapeutics
6.8.1 CARsgen Therapeutics Corporation Information
6.8.2 CARsgen Therapeutics Description and Business Overview
6.8.3 CARsgen Therapeutics Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.8.4 CARsgen Therapeutics Autologous Cell Therapy Products Product Portfolio
6.8.5 CARsgen Therapeutics Recent Developments/Updates
6.9 Sorrento Therapeutics
6.9.1 Sorrento Therapeutics Corporation Information
6.9.2 Sorrento Therapeutics Description and Business Overview
6.9.3 Sorrento Therapeutics Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Sorrento Therapeutics Autologous Cell Therapy Products Product Portfolio
6.9.5 Sorrento Therapeutics Recent Developments/Updates
6.10 Mustang Bio
6.10.1 Mustang Bio Corporation Information
6.10.2 Mustang Bio Description and Business Overview
6.10.3 Mustang Bio Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Mustang Bio Autologous Cell Therapy Products Product Portfolio
6.10.5 Mustang Bio Recent Developments/Updates
6.11 Cellectis
6.11.1 Cellectis Corporation Information
6.11.2 Cellectis Autologous Cell Therapy Products Description and Business Overview
6.11.3 Cellectis Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Cellectis Autologous Cell Therapy Products Product Portfolio
6.11.5 Cellectis Recent Developments/Updates
6.12 Allogene Therapeutics
6.12.1 Allogene Therapeutics Corporation Information
6.12.2 Allogene Therapeutics Autologous Cell Therapy Products Description and Business Overview
6.12.3 Allogene Therapeutics Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Allogene Therapeutics Autologous Cell Therapy Products Product Portfolio
6.12.5 Allogene Therapeutics Recent Developments/Updates
6.13 Celyad Oncology
6.13.1 Celyad Oncology Corporation Information
6.13.2 Celyad Oncology Autologous Cell Therapy Products Description and Business Overview
6.13.3 Celyad Oncology Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Celyad Oncology Autologous Cell Therapy Products Product Portfolio
6.13.5 Celyad Oncology Recent Developments/Updates
6.14 Bluebird Bio
6.14.1 Bluebird Bio Corporation Information
6.14.2 Bluebird Bio Autologous Cell Therapy Products Description and Business Overview
6.14.3 Bluebird Bio Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Bluebird Bio Autologous Cell Therapy Products Product Portfolio
6.14.5 Bluebird Bio Recent Developments/Updates
6.15 Lonza
6.15.1 Lonza Corporation Information
6.15.2 Lonza Autologous Cell Therapy Products Description and Business Overview
6.15.3 Lonza Autologous Cell Therapy Products Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Lonza Autologous Cell Therapy Products Product Portfolio
6.15.5 Lonza Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Autologous Cell Therapy Products Industry Chain Analysis
7.2 Autologous Cell Therapy Products Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Autologous Cell Therapy Products Production Mode & Process
7.4 Autologous Cell Therapy Products Sales and Marketing
7.4.1 Autologous Cell Therapy Products Sales Channels
7.4.2 Autologous Cell Therapy Products Distributors
7.5 Autologous Cell Therapy Products Customers
8 Autologous Cell Therapy Products Market Dynamics
8.1 Autologous Cell Therapy Products Industry Trends
8.2 Autologous Cell Therapy Products Market Drivers
8.3 Autologous Cell Therapy Products Market Challenges
8.4 Autologous Cell Therapy Products Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
